Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2005 Mar;64(Suppl 2):ii65–ii68. doi: 10.1136/ard.2004.031237

Psoriasis assessment tools in clinical trials

S Feldman, G Krueger
PMCID: PMC1766877  PMID: 15708941

Abstract

In clinical practice, broad global assessments of psoriasis disease activity and its effect on patients' quality of life are used to assess the severity of patients' disease and their response to treatment. In clinical trials, more objective, validated instruments are required. Several such instruments have been developed and continue to be developed to provide an assessment of the severity of the skin lesions. Because a lesion's impact on patients' lives varies widely among patients, there has been growing recognition of the need to measure the quality of life impact of the disease along with the severity of the lesions.

Full Text

The Full Text of this article is available as a PDF (61.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson R. T., Aaronson N. K., Wilkin D. Critical review of the international assessments of health-related quality of life. Qual Life Res. 1993 Dec;2(6):369–395. doi: 10.1007/BF00422215. [DOI] [PubMed] [Google Scholar]
  2. Ashcroft D. M., Li Wan Po A., Williams H. C., Griffiths C. E. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther. 1998 Oct;23(5):391–398. doi: 10.1046/j.1365-2710.1998.00181.x. [DOI] [PubMed] [Google Scholar]
  3. Ashcroft D. M., Wan Po A. L., Williams H. C., Griffiths C. E. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999 Aug;141(2):185–191. doi: 10.1046/j.1365-2133.1999.02963.x. [DOI] [PubMed] [Google Scholar]
  4. Brazier J., Jones N., Kind P. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res. 1993 Jun;2(3):169–180. doi: 10.1007/BF00435221. [DOI] [PubMed] [Google Scholar]
  5. Carlin Christopher S., Callis Kristina P., Krueger Gerald G. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol. 2003 Apr;139(4):436–442. doi: 10.1001/archderm.139.4.436. [DOI] [PubMed] [Google Scholar]
  6. Carlin Christopher S., Feldman Steven R., Krueger James G., Menter Alan, Krueger Gerald G. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004 Jun;50(6):859–866. doi: 10.1016/j.jaad.2003.09.014. [DOI] [PubMed] [Google Scholar]
  7. Chren M. M., Lasek R. J., Flocke S. A., Zyzanski S. J. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997 Nov;133(11):1433–1440. [PubMed] [Google Scholar]
  8. Elder James T. Psoriasis clinical registries, genetics, and genomics. Ann Rheum Dis. 2005 Mar;64 (Suppl 2):ii106–ii107. doi: 10.1136/ard.2004.030833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ellis Charles N., Mordin Margaret M., Adler Ellen Y., Randomized, placebo-controlled phase II trial Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003;4(2):131–139. doi: 10.2165/00128071-200304020-00005. [DOI] [PubMed] [Google Scholar]
  10. Feldman Steven R. The design of clinical trials in psoriasis: lessons for clinical practice. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S62–S65. doi: 10.1016/s0190-9622(03)01137-x. [DOI] [PubMed] [Google Scholar]
  11. Finlay A. Y., Khan G. K. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x. [DOI] [PubMed] [Google Scholar]
  12. Fredriksson T., Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244. doi: 10.1159/000250839. [DOI] [PubMed] [Google Scholar]
  13. Gordon Kenneth B., Papp Kim A., Hamilton Tiffani K., Walicke Patricia A., Dummer Wolfgang, Li Nicole, Bresnahan Brian W., Menter Alan, Efalizumab Study Group Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003 Dec 17;290(23):3073–3080. doi: 10.1001/jama.290.23.3073. [DOI] [PubMed] [Google Scholar]
  14. Gottlieb Alice B., Chaudhari Umesh, Baker Daniel G., Perate Michelle, Dooley Lisa T. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol. 2003 Jun;2(3):260–266. [PubMed] [Google Scholar]
  15. Gottlieb Alice B., Chaudhari Umesh, Mulcahy Lisa D., Li Shu, Dooley Lisa T., Baker Daniel G. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003 Jun;48(6):829–835. doi: 10.1067/mjd.2003.307. [DOI] [PubMed] [Google Scholar]
  16. Gottlieb Alice B. Infliximab for psoriasis. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S112–S117. doi: 10.1016/s0190-9622(03)01143-5. [DOI] [PubMed] [Google Scholar]
  17. Gottlieb Alice B., Matheson Robert T., Lowe Nicholas, Krueger Gerald G., Kang Sewon, Goffe Bernard S., Gaspari Anthony A., Ling Mark, Weinstein Gerald D., Nayak Anjuli. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003 Dec;139(12):1627–1632. doi: 10.1001/archderm.139.12.1627. [DOI] [PubMed] [Google Scholar]
  18. Kirby B., Fortune D. G., Bhushan M., Chalmers R. J., Griffiths C. E. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol. 2000 Apr;142(4):728–732. doi: 10.1046/j.1365-2133.2000.03418.x. [DOI] [PubMed] [Google Scholar]
  19. Kirby B., Richards H. L., Woo P., Hindle E., Main C. J., Griffiths C. E. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol. 2001 Jul;45(1):72–76. doi: 10.1067/mjd.2001.114592. [DOI] [PubMed] [Google Scholar]
  20. Krueger J. G., Wolfe J. T., Nabeya R. T., Vallat V. P., Gilleaudeau P., Heftler N. S., Austin L. M., Gottlieb A. B. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med. 1995 Dec 1;182(6):2057–2068. doi: 10.1084/jem.182.6.2057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Langley Richard G., Ellis Charles N. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004 Oct;51(4):563–569. doi: 10.1016/j.jaad.2004.04.012. [DOI] [PubMed] [Google Scholar]
  22. Leonardi Craig L., Powers Jerold L., Matheson Robert T., Goffe Bernard S., Zitnik Ralph, Wang Andrea, Gottlieb Alice B., Etanercept Psoriasis Study Group Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003 Nov 20;349(21):2014–2022. doi: 10.1056/NEJMoa030409. [DOI] [PubMed] [Google Scholar]
  23. Rapp S. R., Feldman S. R., Exum M. L., Fleischer A. B., Jr, Reboussin D. M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):401–407. doi: 10.1016/s0190-9622(99)70112-x. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES